Mar 24, 2025 ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
Mar 13, 2025 ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
Feb 25, 2025 ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
Jan 29, 2025 ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
Jan 10, 2025 ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Nov 14, 2024 ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Nov 12, 2024 ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Oct 30, 2024 ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference